Pediatric neuroblastoma treatment refers to the medical interventions employed to address cancer or tumors affecting the nervous system in children. The treatment approach for neuroblastoma typically involves a combination of surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy.
The primary types of pediatric neuroblastoma treatments include immunotherapy, chemotherapy, radiation therapy, and other supplementary approaches. Immunotherapy is a medical treatment that harnesses the immune system's capabilities to combat diseases. It is applied across different risk groups, including low risk, intermediate risk, and high risk, and is utilized by various end users such as hospitals, specialty clinics, and other medical facilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The pediatric neuroblastoma treatment market research report is one of a series of new reports from The Business Research Company that provides pediatric neuroblastoma treatment market statistics, including pediatric neuroblastoma treatment industry global market size, regional shares, competitors with a pediatric neuroblastoma treatment market share, detailed pediatric neuroblastoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric neuroblastoma treatment industry. This pediatric neuroblastoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pediatric neuroblastoma treatment market size has grown strongly in recent years. It will grow from $1.85 billion in 2024 to $2.02 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to advancements in treatment modalities, increased awareness and early diagnosis, research and development initiatives, collaborative efforts, improved survival rates.
The pediatric neuroblastoma treatment market size is expected to see strong growth in the next few years. It will grow to $2.86 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to emerging therapies, personalized medicine, global health initiatives, expanded access to treatment, patient advocacy and support. Major trends in the forecast period include collaborative research initiatives, gene therapy breakthroughs, novel drug development, early diagnosis and screening, patient advocacy and support.
The forecast of 9.1% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of advanced neuroblastoma therapies by inflating prices of GD2-targeting immunotherapies and MIBG therapy systems developed in the UK and Germany, resulting in delayed treatment initiation and higher pediatric oncology costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The anticipated increase in the number of new cases of pediatric neuroblastoma is poised to drive the growth of the pediatric neuroblastoma treatment market. The rising prevalence of neuroblastoma is fueling the demand for treatment alternatives for pediatric patients. Consequently, pharmaceutical corporations and other stakeholders are intensifying their investments in research and development, fostering innovation in the industry. Additionally, the advent of new diagnostic technology and screening procedures has facilitated the early detection of neuroblastoma, enabling prompt treatment and improved outcomes. For instance, a March 2023 article from the American Society of Clinical Oncology (ASCO) revealed that neuroblastoma affects approximately 700 to 800 youngsters in the United States each year, constituting 6% of all childhood malignancies. Moreover, neuroblastoma impacts around 90% of children under the age of five. Therefore, the increasing incidence of new cases of pediatric neuroblastoma is a significant driver of the pediatric neuroblastoma treatment market.
The ongoing improvement in healthcare infrastructure is expected to contribute to the growth of the pediatric neuroblastoma treatment market. Healthcare infrastructure, encompassing organizational and physical structures, processes, and resources, serves as the foundation for the diagnosis, treatment, and support of pediatric neuroblastoma patients. The various components of healthcare infrastructure collaborate to deliver comprehensive treatment, stimulate research and innovation, and enhance the overall health of children with neuroblastoma. For instance, in March 2022, the Department of Health and Aged Care in Australia announced a record investment of $132 billion in 2022-23 for healthcare infrastructure, with plans to increase it to $140 billion in 2025-26, totaling $537 billion over the next four years. Therefore, the ongoing enhancement of healthcare infrastructure is propelling the pediatric neuroblastoma treatment market.
Major companies in the pediatric neuroblastoma treatment market are focusing on developing technologies such as antibody technologies to enhance the efficacy of targeted therapies and improve patient outcomes. Antibody technologies involve various methods and tools for creating, producing, and utilizing antibodies for diagnostics, therapeutics, and research purposes. For example, in August 2023, Renaissance Pharma Ltd, a UK-based clinical-stage biopharmaceutical company, introduced Hu14.18K322A. This treatment targets GD2, a disialoganglioside found on the surface of neuroblastoma cells. By binding to these cells, Hu14.18K322A recruits immune effector cells to attack and destroy the tumor cells, potentially leading to better treatment outcomes for patients with high-risk neuroblastoma.
Major companies in the pediatric neuroblastoma treatment market are adopting a strategic partnership approach to develop novel drugs for high-risk neuroblastoma. Strategic partnerships involve leveraging each other's strengths and resources for mutual benefits and success. For instance, in August 2023, Renaissance Pharma Ltd., a UK-based biopharmaceutical company, entered into a license agreement with St. Jude Children's Research Hospital for Hu14.18, a humanized antibody developed for managing newly identified high-risk neuroblastoma. Hu14.18, a humanized anti-GD2 monoclonal antibody, demonstrated promising outcomes in a Phase II study, and the licensing agreement grants Renaissance Pharma exclusive development, production, and commercialization rights in various regions, including the United States, Canada, Europe, China, Japan, and Turkey. St. Jude Children's Research Hospital is a renowned US-based research institution.
In March 2022, Recordati S.p.A., an Italy-based pharmaceutical group, acquired EUSA Pharma (UK) Ltd. for $824.28 million. The acquisition is expected to provide Recordati with an expanded portfolio of pharmaceuticals for rare diseases, including treatments for pediatric neuroblastoma. EUSA Pharma (UK) Ltd. is a UK-based specialty pharmaceutical company specializing in pediatric neuroblastoma treatment.
Major companies operating in the pediatric neuroblastoma treatment market include United Therapeutics Corporation, APEIRON Biologics AG, Baxter International Inc., Cell Ectar Biosciences Inc., Pfizer Inc., MacroGenics Inc., Bayer AG, Provectus Biopharmaceuticals Inc., Sartorius AG, Y-mAbs Therapeutics Inc., Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Clarity Pharmaceuticals, CureSearch for Children's Cancer, Novartis AG, Johnson & Johnson Services Inc., AbbVie Inc., Merck & Co. Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd.
North America was the largest region in the pediatric neuroblastoma treatment market in 2024. The regions covered in the pediatric neuroblastoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the pediatric neuroblastoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The pediatric neuroblastoma treatment market consists of revenues earned by entities by providing pediatric neuroblastoma treatment services such as stem cell therapy, supportive care and blood transfusions. The market value includes the value of related goods sold by the service provider or included within the service offering. The pediatric neuroblastoma treatment market also includes sales of pain management medications, chemotherapy drugs and immunotherapy agents which are used in providing pediatric neuroblastoma treatment services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Pediatric Neuroblastoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on pediatric neuroblastoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for pediatric neuroblastoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pediatric neuroblastoma treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment Type: Immunotherapy; Chemotherapy; Radiation Therapy; Other Treatment Types
- 2) By Risk Group: Low Risk; Intermediate Risk; High Risk
- 3) By End User: Hospitals; Specialty Clinics; Other End Users
- Subsegments:
- 1) By Immunotherapy: Monoclonal Antibodies; Immune Checkpoint Inhibitors; CAR T-Cell Therapy
- 2) By Chemotherapy: Alkylating Agents; Antimetabolites; Topoisomerase Inhibitors
- 3) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Radioisotope Therapy
- 4) By Other Treatment Types: Surgery; Stem Cell Transplantation; Targeted Therapy
- Companies Mentioned: United Therapeutics Corporation; APEIRON Biologics AG; Baxter International Inc.; Cell Ectar Biosciences Inc.; Pfizer Inc.; MacroGenics Inc.; Bayer AG; Provectus Biopharmaceuticals Inc.; Sartorius AG; Y-mAbs Therapeutics Inc.; Amgen Inc.; Eli Lilly and Company; F. Hoffmann-La Roche AG; Clarity Pharmaceuticals; CureSearch for Children's Cancer; Novartis AG; Johnson & Johnson Services Inc.; AbbVie Inc.; Merck & Co. Inc.; Bristol-Myers Squibb Company; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company Limited; Eisai Co. Ltd.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Pediatric Neuroblastoma Treatment Market Characteristics
3. Pediatric Neuroblastoma Treatment Market Trends And Strategies
4. Pediatric Neuroblastoma Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Pediatric Neuroblastoma Treatment Growth Analysis And Strategic Analysis Framework
- 5.1. Global Pediatric Neuroblastoma Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Pediatric Neuroblastoma Treatment Market Growth Rate Analysis
- 5.4. Global Pediatric Neuroblastoma Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Pediatric Neuroblastoma Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Pediatric Neuroblastoma Treatment Total Addressable Market (TAM)
6. Pediatric Neuroblastoma Treatment Market Segmentation
- 6.1. Global Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Immunotherapy
- Chemotherapy
- Radiation Therapy
- Other Treatment Types
- 6.2. Global Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Low Risk
- Intermediate Risk
- High Risk
- 6.3. Global Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Specialty Clinics
- Other End Users
- 6.4. Global Pediatric Neuroblastoma Treatment Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Monoclonal Antibodies
- Immune Checkpoint Inhibitors
- CAR T-Cell Therapy
- 6.5. Global Pediatric Neuroblastoma Treatment Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Alkylating Agents
- Antimetabolites
- Topoisomerase Inhibitors
- 6.6. Global Pediatric Neuroblastoma Treatment Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- External Beam Radiation Therapy (EBRT)
- Radioisotope Therapy
- 6.7. Global Pediatric Neuroblastoma Treatment Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Surgery
- Stem Cell Transplantation
- Targeted Therapy
7. Pediatric Neuroblastoma Treatment Market Regional And Country Analysis
- 7.1. Global Pediatric Neuroblastoma Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Pediatric Neuroblastoma Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Pediatric Neuroblastoma Treatment Market
- 8.1. Asia-Pacific Pediatric Neuroblastoma Treatment Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Pediatric Neuroblastoma Treatment Market
- 9.1. China Pediatric Neuroblastoma Treatment Market Overview
- 9.2. China Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Pediatric Neuroblastoma Treatment Market
- 10.1. India Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Pediatric Neuroblastoma Treatment Market
- 11.1. Japan Pediatric Neuroblastoma Treatment Market Overview
- 11.2. Japan Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Pediatric Neuroblastoma Treatment Market
- 12.1. Australia Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Pediatric Neuroblastoma Treatment Market
- 13.1. Indonesia Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Pediatric Neuroblastoma Treatment Market
- 14.1. South Korea Pediatric Neuroblastoma Treatment Market Overview
- 14.2. South Korea Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Pediatric Neuroblastoma Treatment Market
- 15.1. Western Europe Pediatric Neuroblastoma Treatment Market Overview
- 15.2. Western Europe Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Pediatric Neuroblastoma Treatment Market
- 16.1. UK Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Pediatric Neuroblastoma Treatment Market
- 17.1. Germany Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Pediatric Neuroblastoma Treatment Market
- 18.1. France Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Pediatric Neuroblastoma Treatment Market
- 19.1. Italy Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Pediatric Neuroblastoma Treatment Market
- 20.1. Spain Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Pediatric Neuroblastoma Treatment Market
- 21.1. Eastern Europe Pediatric Neuroblastoma Treatment Market Overview
- 21.2. Eastern Europe Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Pediatric Neuroblastoma Treatment Market
- 22.1. Russia Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Pediatric Neuroblastoma Treatment Market
- 23.1. North America Pediatric Neuroblastoma Treatment Market Overview
- 23.2. North America Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Pediatric Neuroblastoma Treatment Market
- 24.1. USA Pediatric Neuroblastoma Treatment Market Overview
- 24.2. USA Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Pediatric Neuroblastoma Treatment Market
- 25.1. Canada Pediatric Neuroblastoma Treatment Market Overview
- 25.2. Canada Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Pediatric Neuroblastoma Treatment Market
- 26.1. South America Pediatric Neuroblastoma Treatment Market Overview
- 26.2. South America Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Pediatric Neuroblastoma Treatment Market
- 27.1. Brazil Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Pediatric Neuroblastoma Treatment Market
- 28.1. Middle East Pediatric Neuroblastoma Treatment Market Overview
- 28.2. Middle East Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Pediatric Neuroblastoma Treatment Market
- 29.1. Africa Pediatric Neuroblastoma Treatment Market Overview
- 29.2. Africa Pediatric Neuroblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Pediatric Neuroblastoma Treatment Market, Segmentation By Risk Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Pediatric Neuroblastoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Pediatric Neuroblastoma Treatment Market Competitive Landscape And Company Profiles
- 30.1. Pediatric Neuroblastoma Treatment Market Competitive Landscape
- 30.2. Pediatric Neuroblastoma Treatment Market Company Profiles
- 30.2.1. United Therapeutics Corporation Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. APEIRON Biologics AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Cell Ectar Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Pediatric Neuroblastoma Treatment Market Other Major And Innovative Companies
- 31.1. MacroGenics Inc.
- 31.2. Bayer AG
- 31.3. Provectus Biopharmaceuticals Inc.
- 31.4. Sartorius AG
- 31.5. Y-mAbs Therapeutics Inc.
- 31.6. Amgen Inc.
- 31.7. Eli Lilly and Company
- 31.8. F. Hoffmann-La Roche AG
- 31.9. Clarity Pharmaceuticals
- 31.10. CureSearch for Children's Cancer
- 31.11. Novartis AG
- 31.12. Johnson & Johnson Services Inc.
- 31.13. AbbVie Inc.
- 31.14. Merck & Co. Inc.
- 31.15. Bristol-Myers Squibb Company
32. Global Pediatric Neuroblastoma Treatment Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Pediatric Neuroblastoma Treatment Market
34. Recent Developments In The Pediatric Neuroblastoma Treatment Market
35. Pediatric Neuroblastoma Treatment Market High Potential Countries, Segments and Strategies
- 35.1 Pediatric Neuroblastoma Treatment Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Pediatric Neuroblastoma Treatment Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Pediatric Neuroblastoma Treatment Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
